Earnings summaries and quarterly performance for ARTELO BIOSCIENCES.
Executive leadership at ARTELO BIOSCIENCES.
Board of directors at ARTELO BIOSCIENCES.
Research analysts covering ARTELO BIOSCIENCES.
Recent press releases and 8-K filings for ARTL.
Artelo Biosciences Secures Up to $50 Million Equity Financing Facility
ARTL
- Artelo Biosciences, Inc. entered into an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5 on January 30, 2026.
- The agreement grants the Company the right, but not the obligation, to sell up to $25 million of its common stock to Square Gate, with an option for an additional $25 million upon exhaustion of the initial amount.
- The purchase price for shares will be 95% of the lowest daily VWAP during the three trading days following a Put Notice.
- In consideration for the agreement, Artelo Biosciences will issue 292,398 shares of Common Stock to Square Gate, valued at $500,000 as of January 30, 2026, and cover up to $35,000 in fees.
- The agreement is effective until the earlier of Square Gate purchasing the maximum commitment amount or January 30, 2029.
1 day ago
Artelo Biosciences Comments on Medicare CBD Pilot Program and Highlights ART12.11
ARTL
New Projects/Investments
Regulatory Update
- Artelo Biosciences commented on a White House Executive Order establishing a Medicare pilot program for cannabidiol (CBD) products, viewing it as a significant milestone for medical CBD and improving access to cannabinoid-based treatments.
- The company is prepared to advance ART12.11, its proprietary cocrystal composition of CBD and tetramethylpyrazine (TMP), into human clinical trials following constructive feedback from regulatory authorities.
- ART12.11 has demonstrated superior oral bioavailability, more consistent pharmacokinetics, and enhanced efficacy signals in preclinical models of anxiety and depression compared to standard CBD formulations.
- The Drug Enforcement Agency (DEA) has informed Artelo that ART12.11 would not be considered a controlled drug, and its US composition of matter patent is enforceable until December 10, 2038.
Dec 23, 2025, 2:00 PM
Artelo Biosciences, Inc. Issues Convertible Notes and Warrants
ARTL
Debt Issuance
- Artelo Biosciences, Inc. completed an offering on October 28, 2025, issuing convertible notes with an aggregate principal amount of $690,154.69 and warrants to purchase 438,182 shares of common stock. This offering converted a portion of the unpaid principal and accrued interest from prior May 2025 convertible notes that matured on the same date.
- The convertible notes bear an interest rate of 12% per annum, increasing to 20% upon an Event of Default, and are due on April 28, 2026. They are convertible into common stock at a price of $3.40 per share.
- The accompanying warrants are exercisable for five years at an exercise price of $3.40 per share. The company committed to filing a registration statement for the resale of the underlying shares within 20 calendar days of the closing.
Oct 31, 2025, 12:00 PM
Artelo Biosciences Announces Closing of $2.0 Million Public Offering
ARTL
New Projects/Investments
- Artelo Biosciences, Inc. closed its underwritten public offering on October 1, 2025.
- The offering generated approximately $2.0 million in aggregate gross proceeds.
- The offering consisted of 441,210 shares of common stock at $4.40 per share and pre-funded warrants to purchase up to 13,335 shares at $4.399 per pre-funded warrant.
- The company granted the underwriters a 45-day option to purchase up to an additional 68,181 shares of common stock.
- Net proceeds from the offering are intended to advance product candidates through preclinical and clinical development, and for working capital and general corporate purposes.
Oct 1, 2025, 9:28 PM
Fintool News
In-depth analysis and coverage of ARTELO BIOSCIENCES.
Quarterly earnings call transcripts for ARTELO BIOSCIENCES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more